Floatz logo

Neo-Pv-01

Bladder Tumors

BioNTech US Inc.vaccinePhase 1Dormant
CC
47/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
95/ 100

Competitive context

24 Active assets in the Bladder Tumors cohort.

Asset / SponsorPhaseRating
Carboplatin
Merck Sharp & Dohme LLC
Phase 2BB
ENFORTUMAB VEDOTIN (fully human monoclonal antibody conjugated to a cytotoxic agent monomethyl auristatin E (MMAE) targeting nectin-4)
Eli Lilly and Company
Phase 2BB
CIS-DIAMMINEDICHLOROPLATINUM II
Merck Sharp & Dohme LLC
Phase 2BB
Pembrolizumab
Eli Lilly and Company
Phase 2BB
Nivolumab
Ikena Oncology
Phase 2B

View all 37 →

Same molecule, other indications

Neo-Pv-01 is also rated in:

Nonsquamous Nonsmall Cell Neoplasm of LungDormant
CC
Indicative ·
47 / 100
View asset →
urinary bladder cancerDormant
CC
Indicative ·
47 / 100
View asset →
bladder transitional cell carcinomaDormant
CC
Indicative ·
47 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →